BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35357510)

  • 1. T2 mapping for the characterization of prostate lesions.
    Hepp T; Kalmbach L; Kolb M; Martirosian P; Hilbert T; Thaiss WM; Notohamiprodjo M; Bedke J; Nikolaou K; Stenzl A; Kruck S; Kaufmann S
    World J Urol; 2022 Jun; 40(6):1455-1461. PubMed ID: 35357510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MR Fingerprinting and ADC Mapping for Characterization of Lesions in the Transition Zone of the Prostate Gland.
    Panda A; Obmann VC; Lo WC; Margevicius S; Jiang Y; Schluchter M; Patel IJ; Nakamoto D; Badve C; Griswold MA; Jaeger I; Ponsky LE; Gulani V
    Radiology; 2019 Sep; 292(3):685-694. PubMed ID: 31335285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of T
    Klingebiel M; Schimmöller L; Weiland E; Franiel T; Jannusch K; Kirchner J; Hilbert T; Strecker R; Arsov C; Wittsack HJ; Albers P; Antoch G; Ullrich T
    J Magn Reson Imaging; 2022 Aug; 56(2):413-422. PubMed ID: 35038203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T1 Mapping of the Prostate Using Single-Shot T1FLASH: A Clinical Feasibility Study to Optimize Prostate Cancer Assessment.
    Al-Bourini O; Seif Amir Hosseini A; Giganti F; Balz J; Heitz LG; Voit D; Lotz J; Trojan L; Frahm J; Uhlig A; Uhlig J
    Invest Radiol; 2023 Jun; 58(6):380-387. PubMed ID: 36729865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostatitis, the Great Mimicker of Prostate Cancer: Can We Differentiate Them Quantitatively With Multiparametric MRI?
    Uysal A; Karaosmanoğlu AD; Karcaaltıncaba M; Akata D; Akdogan B; Baydar DE; Ozmen MN
    AJR Am J Roentgenol; 2020 Nov; 215(5):1104-1112. PubMed ID: 32901562
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of Diffusion Kurtosis Imaging Versus Standard Diffusion Imaging for Detection and Grading of Peripheral Zone Prostate Cancer.
    Roethke MC; Kuder TA; Kuru TH; Fenchel M; Hadaschik BA; Laun FB; Schlemmer HP; Stieltjes B
    Invest Radiol; 2015 Aug; 50(8):483-9. PubMed ID: 25867657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Combined MR Fingerprinting and Diffusion Examination for Prostate Cancer.
    Yu AC; Badve C; Ponsky LE; Pahwa S; Dastmalchian S; Rogers M; Jiang Y; Margevicius S; Schluchter M; Tabayoyong W; Abouassaly R; McGivney D; Griswold MA; Gulani V
    Radiology; 2017 Jun; 283(3):729-738. PubMed ID: 28187264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Biopsy Validation of Peripheral Zone Prostate Cancer Characterization With Magnetic Resonance Fingerprinting and Diffusion Mapping.
    Panda A; OʼConnor G; Lo WC; Jiang Y; Margevicius S; Schluchter M; Ponsky LE; Gulani V
    Invest Radiol; 2019 Aug; 54(8):485-493. PubMed ID: 30985480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic-Based Model vs. PI-RADS v2.
    Chen T; Li M; Gu Y; Zhang Y; Yang S; Wei C; Wu J; Li X; Zhao W; Shen J
    J Magn Reson Imaging; 2019 Mar; 49(3):875-884. PubMed ID: 30230108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffusion-weighted magnetic resonance imaging in the prostate transition zone: histopathological validation using magnetic resonance-guided biopsy specimens.
    Hoeks CM; Vos EK; Bomers JG; Barentsz JO; Hulsbergen-van de Kaa CA; Scheenen TW
    Invest Radiol; 2013 Oct; 48(10):693-701. PubMed ID: 23614975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of prostatitis and prostate cancer using the Prostate Imaging-Reporting and Data System (PI-RADS).
    Meier-Schroers M; Kukuk G; Wolter K; Decker G; Fischer S; Marx C; Traeber F; Sprinkart AM; Block W; Schild HH; Willinek W
    Eur J Radiol; 2016 Jul; 85(7):1304-11. PubMed ID: 27235878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center.
    Hermie I; Van Besien J; De Visschere P; Lumen N; Decaestecker K
    Eur J Radiol; 2019 May; 114():92-98. PubMed ID: 31005183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI-RADS v2 and ADC values: is there room for improvement?
    Jordan EJ; Fiske C; Zagoria R; Westphalen AC
    Abdom Radiol (NY); 2018 Nov; 43(11):3109-3116. PubMed ID: 29550953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative contrast-enhanced perfusion kinetics in multiparametric MRI in differentiating prostate cancer from chronic prostatitis: results from a pilot study.
    Sureka B; Elhence P; Khera PS; Choudhary GR; Pandey H; Garg PK; Yadav K; Goel A
    Br J Radiol; 2019 Aug; 92(1100):20190181. PubMed ID: 31184934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Evaluation of late Gadolinium Enhancement to the Differential Diagnosis of Prostate Cancer and Prostatitis in mpMRI.
    Aydin H; Topsakal K; Ayyildiz VA; Aydin H; Karaibrahimoglu A
    J Coll Physicians Surg Pak; 2023 Jan; 33(1):20-26. PubMed ID: 36597230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer.
    Xu L; Zhang G; Shi B; Liu Y; Zou T; Yan W; Xiao Y; Xue H; Feng F; Lei J; Jin Z; Sun H
    Cancer Imaging; 2019 Dec; 19(1):90. PubMed ID: 31864408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The value of relaxation time quantitative technique from synthetic magnetic resonance imaging in the diagnosis and invasion assessment of prostate cancer].
    Song N; Wang T; Zhang D; Wang Z; Zhang SR; Yu J; Cai L; Ma AL; Zhang Q; Chen ZQ
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(15):1093-1099. PubMed ID: 35436808
    [No Abstract]   [Full Text] [Related]  

  • 19. Detection of clinically signifi cant prostate cancer with PIRADS v2 scores, PSA density, and ADC values in regions with and without mpMRI visible lesions.
    Westphalen AC; Fazel F; Nguyen H; Cabarrus M; Hanley-Knutson K; Shinohara K; Carroll PR
    Int Braz J Urol; 2019; 45(4):713-723. PubMed ID: 31136112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative Biopsy Histology in Men With PI-RADS Score 5 in Daily Clinical Practice: Incidence of Granulomatous Prostatitis.
    Pepe P; Pennisi M
    Clin Genitourin Cancer; 2020 Dec; 18(6):e684-e687. PubMed ID: 32389459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.